Compare Bristol-Myers Squibb Co (BMY) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MakeMyTrip Ltd — how do they compare? Bristol-Myers Squibb Co trades at $58.93 (market cap $116.30B), while MakeMyTrip Ltd trades at $57.08 (market cap $5.29B). The key difference: Bristol-Myers Squibb Co is far larger — about 22× MakeMyTrip Ltd's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| BMY | MMYT | |
|---|---|---|
Market Cap | $116.30B | $5.29B |
Sector | Health | Technology |
52-Week High | $62.37 | $103.21 |
52-Week Low | $42.60 | $36.30 |
Enterprise Value | $152.24B | $5.93B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MakeMyTrip (MMYT) trades at $57.08, down 2.63% today but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with $978M revenue and $95M net income for 2025, though 2026 projections show margin compression. Recent earnings beats and a 73% gross margin highlight operational strength, while technical indicators show bullish moving averages despite recent price weakness.
The stock presents a compelling growth opportunity with strong analyst consensus (73% buy ratings) and consistent earnings outperformance. However, elevated P/E ratio (154.86) and projected margin pressure in 2026 warrant caution. Key risks include travel industry volatility and rising debt-to-asset ratio from 12% to 81% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
